Remote Fetal Monitoring Closes Adherence Gap in High-Risk Pregnancies

AVENTURA, FL – November 05, 2026 – For women navigating high-risk pregnancies, the final weeks are often a grueling marathon of medical appointments. Prescribed non-stress tests (NSTs) to monitor fetal well-being frequently require clinic visits once or twice a week. For many, this schedule is a logistical nightmare involving lost wages, childcare scrambling, and transportation hurdles. Today, new data suggests that moving this critical surveillance from the clinic to the living room could not only alleviate these burdens but fundamentally reshape obstetrical care.

Nuvo Intl Group Inc., a women’s health technology company, announced the results of the REACTIVE trial, a randomized clinical trial evaluating its FDA-cleared INVU remote fetal monitoring platform. Conducted by researchers at the Perelman School of Medicine at the University of Pennsylvania and funded by the National Institutes of Health (NIH), the study of 385 high-risk pregnancies delivered a striking verdict: self-administered at-home monitoring significantly improved adherence to prescribed testing while halving the number of required in-person visits to the fetal testing unit.

Crucially, this shift occurred with no compromise to clinical safety. Rates of non-reactive tests, recommendations for delivery, cesarean sections, and neonatal intensive care unit (NICU) admissions remained statistically equivalent between the remote and in-office cohorts.

Bridging the Maternal Health Divide

The most profound revelation of the REACTIVE trial lies in its demographic breakdown. In the United States, maternal health outcomes are deeply fractured along socioeconomic lines, and access to consistent prenatal surveillance is a well-documented pain point.

In the trial, privately insured participants achieved 100 percent adherence regardless of whether they were assigned to remote or in-office testing. However, among publicly insured participants, the disparity was stark. Median adherence was 73.0 percent with remote testing versus just 60.0 percent with in-office testing. Furthermore, nearly half (48.7 percent) of all women in the remote group completed their entire prescribed testing schedule, compared to only a third (33.9 percent) in the in-office group.

"Fetal monitoring is critical in high-risk pregnancies. It helps us recognize when a baby may be in distress and when closer evaluation or earlier delivery may be necessary," said Dr. Nadav Schwartz, Professor of Obstetrics and Gynecology at the Perelman School of Medicine, principal investigator of the NIH award, and a member of Nuvo's Advisory Board. "What's especially encouraging about these findings is that women were able to complete more of this essential monitoring with substantially fewer routine testing visits, including women who often face the greatest barriers to care."

Independent experts view this as a critical step toward equity. "When you look at the maternal mortality and morbidity crisis in this country, a significant driver is missed interventions due to missed appointments," noted an independent maternal-fetal medicine specialist familiar with the trial's design. "Technology that removes the transportation and hourly-wage penalties for low-income mothers isn't just a convenience feature; it is a vital health equity intervention."

Decongesting the Clinic: The Operational Shift

Beyond patient convenience, the REACTIVE trial presents a compelling operational case for overburdened health systems. Women in the remote group averaged 3.3 visits to the fetal testing unit, compared to 6.3 in the in-office group. By effectively cutting foot traffic in half, hospitals can potentially reclaim valuable physical space and reallocate clinical staff to more acute, hands-on care.

However, remote care does not mean automated care. All NSTs in the remote group were interpreted in real-time by a clinical team using a dedicated digital dashboard. Interestingly, the trial noted that tests took modestly longer in the remote group—averaging 35.1 minutes on the monitor versus 27.5 minutes in the clinic.

"The slight increase in monitoring time is a worthwhile trade-off," an obstetrical department administrator observed. "The real bottleneck in maternal care isn't the time spent reading a strip on a dashboard; it's the physical throughput of patients in a waiting room, the room turnover, and the staffing required to physically manage an in-person visit."

The long-term viability of this model will heavily depend on the evolving reimbursement landscape. While remote physiological monitoring (RPM) codes have gained immense traction since the COVID-19 pandemic, adapting traditional CPT codes for non-stress tests to a remote environment remains a complex hurdle. Broad adoption will require state Medicaid programs and commercial insurers to recognize the economic value—fewer facility fees and potentially better preventative outcomes—and establish clear, sustainable payment pathways for remote obstetrics.

The Evolution of Prenatal Surveillance

The INVU platform also represents a significant technological departure from the standard of care. For decades, fetal surveillance has relied on Doppler ultrasound transducers strapped to the mother's abdomen by a trained technician. This method, while highly effective in a clinical setting, requires precise placement and constant readjustment to maintain a signal, making it largely unsuitable for unsupervised home use.

Nuvo's approach discards ultrasound entirely. The INVU system utilizes a wearable band equipped with a sophisticated array of passive biopotential electrodes and acoustic sensors. These sensors capture the electrical (ECG) and acoustic (phonocardiographic) signals of both the maternal and fetal hearts, alongside motion sensors to track maternal movement.

The raw data is then transmitted wirelessly to a cloud platform, where proprietary signal-processing algorithms separate the fetal heartbeat from the maternal heartbeat and estimate uterine activity. This passive data collection not only simplifies the user experience—allowing a mother to initiate the test via a mobile app without a technician in the room—but also eliminates lingering consumer concerns regarding repeated ultrasound exposure over the course of a long pregnancy.

Navigating Conflicts and Future Adoption

While the REACTIVE trial provides robust, peer-reviewed evidence, industry observers will naturally scrutinize the relationships behind the research. Nuvo provided the INVU systems used in the study, and Dr. Schwartz, the principal investigator of the NIH award, sits on the company's Advisory Board.

Despite these industry ties, the trial's sponsorship by the University of Pennsylvania, its randomized design, and its funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) lend substantial credibility to the findings. Health systems are notoriously cautious about altering established clinical pathways, typically demanding rigorous, randomized data before deploying new technologies at scale.

By demonstrating that decentralized, wearable antepartum monitoring can drastically reduce healthcare utilization and ease socioeconomic barriers without compromising diagnostic efficacy, the REACTIVE trial offers exactly the kind of evidence administrators and payers require. As maternity care deserts expand and health systems search for scalable solutions to manage high-risk populations, moving the non-stress test from the clinic to the living room may soon transition from a novel experiment to a standard expectation.